M Jabri

Netherlands Cancer Institute, Amsterdamo, North Holland, Netherlands

Are you M Jabri?

Claim your profile

Publications (3)5.01 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: In the subrenal capsule assay, the immuno-competent mice used have a host immune response to the graft which may introduce a bias in the determination of tumour size. A study was therefore conducted to verify the quality of the correlation that could exist between "macroscopical" and "microscopical" evaluation. A histological study of 12 different tumours treated with cis-Pt, L-PAM, DTIC, vindesine, BCNU or TGU demonstrated that a cellular host immune response was observed in 11 out of the 12 control groups and was uneven in the treated groups. The "microscopical" and "macroscopical" evaluations of tumour-take were 100 and 95% respectively. Although there was a fair correlation between the "microscopic" and "macroscopic" parameters, tumour variations in absence of host reaction--which reflect pure chemosensitivity of the treated tissue--could be measured in 50% of the cases. It was possible to determine a base-line for rejection of the test results when the control group showed a decrease in mean tumour size exceeding 20% of its initial size on day 0. If the decrease is less than 20%, then the histological evaluation appears to be of considerable additional value.
    International Journal of Cancer 04/1984; 33(4):447-51. DOI:10.1002/ijc.2910330405 · 5.01 Impact Factor
  • F J Lejeune · R Regnier · J M Nogaret · M Jabri
    [Show abstract] [Hide abstract]
    ABSTRACT: In order to avoid amputation, which does not seem to improve survival in osteosarcoma, we have initiated a limb-preservation program using intra-arterial radiosensitization. Eleven osteosarcomas with soft tissue involvement and six other bone malignancies were prospectively treated according to the following protocol: (a) surgical insertion of an intra-arterial catheter through a Dacron patch, (b) intra-arterial infusion of 15 mg/kg BUDR on days 1-2 every 5 days for 40 days, (c) 600 rads flash irradiation on day 3 every 5 days, X 8. Median follow-up time has been 36 months. In the osteosarcoma group, median survival has been 12 months. Four of the five osteosarcoma patients who died had received prophylactic HD methotrexate-vincristine-adriamycin systemic chemotherapy; one patient refused.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 02/1983; 86:204-8.
  • Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 02/1983; 86:268-76. DOI:10.1007/978-3-642-82025-0_45